Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431323 | 0.77 | ELANE (0.40) | EGFRPDE1BHPGDKDM4EALDH1A1 | |
| SCHEMBL26313711 | 0.77 | EGFR (0.52) | EGFRKCNA5HPGDKDM4EALDH1A1 | |
| SCHEMBL21347900 | 0.77 | ELANE (0.42) | EGFRELANEMEN1KMT2A | |
| SCHEMBL21340329 | 0.76 | PARP1 (0.41) | EGFRPDE1BALDH1A1ERBB2FGFR2 | |
| SCHEMBL1478679 | 0.76 | KMT2A (0.54) | EGFRKCNA5HPGDKDM4EALDH1A1 | |
| SCHEMBL22644982 | 0.76 | PDE1B (0.48) | EGFRPDE1BHPGDNQO2MEN1 | |
| SCHEMBL30782464 | 0.76 | KMT2A (0.54) | EGFRKCNA5HPGDKDM4EALDH1A1 | |
| SCHEMBL3429487 | 0.76 | EGFR (0.51) | EGFRKCNA5HPGDKDM4EALDH1A1 | |
| SCHEMBL21937410 | 0.76 | PARP1 (0.41) | EGFRPDE1BMEN1KMT2A | |
| SCHEMBL18312193 | 0.76 | DCPS (0.60) | EGFRKCNA5HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11560376-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210017171-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-10793564-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | EGFR 457/4885KCNA5 1439/4885PDE1B 4133/4885 |
| US-11419869-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | EGFR 463/4885KCNA5 1269/4885PDE1B 3936/4885 |
| US-10793564-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | EGFR 457/4885KCNA5 1439/4885PDE1B 4133/4885 |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | EGFR 457/4885KCNA5 1439/4885PDE1B 4133/4885 |
| US-20210017171-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | EGFR 457/4885KCNA5 1439/4885PDE1B 4133/4885 |
| US-20200352942-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | ITGB6, ITGA6, ITGAV | EGFR 463/4885KCNA5 1269/4885PDE1B 3936/4885 |
| US-11560376-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | EGFR 457/4885KCNA5 1439/4885PDE1B 4133/4885 |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | EGFR 932/4885KCNA5 718/4885PDE1B 3313/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | EGFR 769/4885KCNA5 1049/4885PDE1B 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.